Propanc Biopharma Secures Key Assay for Phase 1b First-In-Human Cancer Drug Study
PPCB is trading near its 52-week low of $0.156 (2.6% above the low).
Summary
Propanc Biopharma has executed a service agreement with FyoniBio to establish and validate a pharmacokinetics (PK) assay for its lead asset, PRP. This assay is a critical preparatory step for the company's planned Phase 1b First-In-Human (FIH) study in advanced cancer patients, which is targeted to commence in the fourth calendar quarter of this year. The news follows recent positive preclinical data for PRP and the appointment of Dr. Ralf Brandt, who highlighted this as one of three key activities for the pivotal milestone. For a micro-cap biopharma company, this represents tangible progress in advancing its lead drug candidate into clinical trials, a significant de-risking event that could drive future value. Investors will now watch for the successful completion of GMP manufacturing, the clinical trial application, and the commencement of the FIH study.
At the time of this announcement, PPCB was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $0.16 to $24.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.